Expanded Access INDs: FDA’s Near-Perfect Approval Rate Underscores Problems, Advocates Say
Executive Summary
CDER continues to allow most submissions it receives for access to investigational drugs but critics say barriers prevent vast numbers of patients from requesting access.
You may also be interested in...
FDA Expanded Access Guidances Fail To Achieve Détente With Advocates
The number of requests to use investigational drugs outside of clinical trials has grown and FDA typically approves all requests, but advocates still insist the process is set up to fail patients.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.